First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients
Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture
Construction of the plant will commence in 2025 with first production expected to be in 2027
SIBUR is developing a special grade of polycarbonate compatible with radiation sterilization
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
Phase 2 Study of MK-2060 Currently Ongoing in People with End-Stage Renal Disease Receiving Hemodialysis
Therapy recently approved in Canada under the brand name KORSUVA
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Subscribe To Our Newsletter & Stay Updated
